Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis. A multi-center, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis. A multi-center, double-blind, placebo-controlled trial

Published:1989-07 Issue:1 Volume:55 Page:13-23
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Publisher

Elsevier BV

Subject

Hematology

Reference38 articles.

1. Receptor binding profile of R 41468, a novel antagonist at 5-HT2 receptors;Leysen;Life Sci.,1981

2. Serotonergic mechanisms in hypertension;Vanhoutte,1988

3. Vascular effects of ketanserin (R 41468), a novel antagonist of 5-HT2 serotonergic receptors;Van Nueten;J. Pharmacol. Exp. Therap.,1981

4. Platelet-vessel wall interactions: implication of 5-hydroxytryptamine;De Clerck,1984

5. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41468), a selective 5-HT2-receptor antagonist;De Clerck;Agents Actions,1982

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications;Blood;2007-08-15

2. In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis;Clinical Therapeutics;2004-08

3. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline;British Journal of Pharmacology;1992-08

4. Ridogrel in the setting of percutaneous transluminal coronary angioplasty;The American Journal of Cardiology;1991-08